Medical Devices and Biopharmaceuticals
Search documents
Beyond Air® Comments on Landmark Independent Review Article Highlighting the Antimicrobial Effects of High-Dose Inhaled Nitric Oxide and its Therapeutic Potential for Treating Respiratory Infections
Globenewswire· 2026-02-20 13:00
GARDEN CITY, N.Y., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today commented on the publication of an independent review article providing the most comprehensive overview to date of high‑dose inhaled nitric oxide (iNO) delivered at concentrations well above the FDA‑approved 20 ppm, and presenting mounti ...
Fractyl Health(GUTS) - Prospectus(update)
2024-01-29 11:09
Table of Contents Registration No. 333-276046 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 1 to Index to Financial Statements FORM S-1 REGISTRATION STATEMENT UNDER As filed with the Securities and Exchange Commission on January 29, 2024. THE SECURITIES ACT OF 1933 FRACTYL HEALTH, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 3841 27-3553477 (Primary Standard Industrial Classificatio ...